Literature DB >> 11595764

Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat.

T Moos1, E H Morgan.   

Abstract

Anti-transferrin receptor IgG2a (OX26) transport into the brain was studied in rats. Uptake of OX26 in brain capillary endothelial cells (BCECs) was > 10-fold higher than isotypic, non-immune IgG2a (Ni-IgG2a) when expressed as % ID/g. Accumulation of OX26 in the brain was higher in 15 postnatal (P)-day-old rats than in P0 and adult (P70) rats. Iron-deficiency did not increase OX26 uptake in P15 rats. Three attempts were made to investigate transport from BCECs further into the brain. (i) Using a brain capillary depletion technique, 6-9% of OX26 was identified in the post-capillary compartment consisting of brain parenchyma minus BCECs. (ii) In cisternal CSF, the volume of distribution of OX26 was higher than for Ni-IgG2a when corrected for plasma concentration. (iii) Immunohistochemical mapping revealed the presence of OX26 almost exclusively in BCECs; extravascular staining was observed only in neurons situated periventricularly. The data support the hypothesis of facilitated uptake of OX26 due to the presence of transferrin receptors at the blood-brain barrier (BBB). However, OX26 accumulation in the post-capillary compartment was too small to justify a conclusion of receptor-mediated transcytosis of OX26 occurring in BCECs. Accumulation of OX26 in the post-capillary component may result from a diphasic transport that involves high-affinity accumulation of OX26 by the BCECs, clearly exceeding that of Ni-IgG2a, followed by a second transport mechanism that releases OX26 non-specifically further into the brain. The periventricular localization suggests that OX26 probably also derives from transport across the blood-CSF barrier.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595764     DOI: 10.1046/j.1471-4159.2001.00541.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  44 in total

1.  Transferrin antibodies into the brain.

Authors:  Mark S Dennis; Ryan J Watts
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  Strategies to improve drug delivery across the blood-brain barrier.

Authors:  Albertus G de Boer; Pieter J Gaillard
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

4.  Pharmacokinetics of an intracerebroventricularly administered antibody in rats.

Authors:  Yuki Noguchi; Motohiro Kato; Kazuhisa Ozeki; Masaki Ishigai
Journal:  MAbs       Date:  2017-07-06       Impact factor: 5.857

Review 5.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

6.  In vitro models of molecular and nano-particle transport across the blood-brain barrier.

Authors:  Cynthia Hajal; Marco Campisi; Clara Mattu; Valeria Chiono; Roger D Kamm
Journal:  Biomicrofluidics       Date:  2018-05-31       Impact factor: 2.800

7.  Antibody pharmacokinetics in rat brain determined using microdialysis.

Authors:  Hsueh-Yuan Chang; Kasey Morrow; Emily Bonacquisti; WanYing Zhang; Dhaval K Shah
Journal:  MAbs       Date:  2018-08-06       Impact factor: 5.857

Review 8.  Imaging of cells and nanoparticles: implications for drug delivery to the brain.

Authors:  Katica Stojanov; Inge S Zuhorn; Rudi A J O Dierckx; Erik F J de Vries
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

Review 9.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 10.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.